HealthTree Logo
search more_vert
person Sign In / Create Account
The World's Largest Myeloma Screening Study (PROMISE) with Irene Ghobrial, MD, Dana Farber Cancer Institute
The World's Largest Myeloma Screening Study (PROMISE) with Irene Ghobrial, MD, Dana Farber Cancer Institute image
HealthTree Podcast for Multiple Myeloma
event Sep 04, 2019 / 11:00AM MDT

Event Description

Irene Ghobrial, MD
Dana Farber Cancer Institute 
Interview Date: September 4, 2019

The PROMISE study is the world's largest screening study for multiple myeloma and is led by top myeloma researchers Dr. Irene Ghobrial of the Dana Farber Cancer Institute and Dr. Ivan Borrello of Johns Hopkins. Dr. Ghobrial plans to invite 50,000 participants that include two key groups of people who are more likely to develop multiple myeloma. The first group is family members between the ages of 40-75 of myeloma, MGUS or smoldering myeloma patients. The second group is all African Americans, who are 3 times as likely to develop multiple myeloma. Learn how your friends and family can join this important study that will tell us why myeloma develops and how we may be able to receive earlier, better treatment that could prevent it from developing into active myeloma in the first place. 

Please share this important study with at least 5 friends and family members today! 

Thanks to our episode sponsor


Schedule & Agenda

Dr. Irene Ghobrial

Speakers & Moderators

The panelist Irene Ghobrial, MD
Irene Ghobrial, MD

Irene Ghobrial, MD, is a Professor at the Dana-Farber Cancer Institute (DFCI), Harvard Medical School and an associate member of the Broad Institute. She is Director of the Michele & Stephen Kirsch Laboratory and co-director of the Center for Prevention of Progression (CPOP) at DFCI. Additionally, she is the co-leader of the Blood Cancer Research Partnership (BCRP), a consortium for innovative clinical trials of community oncology sites coordinated by DFCI. Dr. Ghobrial’s research focuses on understanding mechanisms of tumor progression from early precursor conditions such as monoclonal gammopathy of undetermined significance (MGUS) and smoldering disease to symptomatic multiple myeloma and Waldenström Macroglobulinemia. She specifically focuses on the role of malignant bone marrow niche in regulating disease progression. She is interested in the development of new molecular/genomic markers that predict progression in precursor conditions which can identify patients who should be eligible for therapeutic interventions to prevent progression or potentially cure the disease at the early stages before clonal evolution occurs. She has authored or co-authored more than 250 publications and book chapters. She has received multiple awards including membership in the American Society of Clinical Investigation, the Robert A. Kyle Award for Research in Waldenström Macroglobulinemia, and the Mentor of the Year Award at DFCI in 2014. Dr. Ghobrial completed her hematology/oncology subspecialty training at the Mayo Clinic College of Medicine in Rochester, MN and internal medicine training at Wayne State University in Detroit, MI. She earned her medical degree from the Cairo School of Medicine in Egypt.

Read Bio
The panelist Jennifer Ahlstrom
Jennifer Ahlstrom

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of the HealthTree Foundation.

Read Bio

Have Any Questions?

Thank you for your interest in the event. If you have any questions, we would love to help!

Feel free to give us a call or send us a message below.


Get In Touch With Us




Get the latest thought leadership on Multiple Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Multiple Myeloma Newsletter" for Multiple Myeloma news, life with Multiple Myeloma stories, Multiple Myeloma clinical trials, Multiple Myeloma 101 articles and events with Multiple Myeloma experts.

Thanks to our HealthTree Community for Multiple Myeloma Sponsors:

Johnson and Johnson
Bristol Myers Squibb

Follow Us

facebook instagram linkedin tiktok youtube